Orthofix Medical, Inc. OFIX
NASDAQ · United States · Health Technology
$9.09-0.12 (-1.30%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Orthofix Medical Inc (OFIX) delivers 5% pro forma growth, raises EBITDA guidance, and navigates a complex landscape of European MDR opportunities and U.S. distributor headwinds.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.